Optimized antigens of pneumocystis and use thereof
US9512189B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Aug 6, 2012 |
| Grant date | Dec 6, 2016 |
| Priority date | — |
| Expiry date | Dec 14, 2032 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/55566
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Immunologically active agents are described, including isolated Pneumocystis A 12 protein or polypeptides; immunogenic conjugates containing Pneumocystis A 12 protein or polypeptide of the present invention; antibodies recognizing the Pneumocystis A 12 protein or polypeptide or the immunogenic conjugates of the present invention; and nucleic acid molecules that encode the Pneumocystis A 12 protein or polypeptide of the present invention, as well as DNA constructs, expression vectors, and host cells that contain the nucleic acid molecules. Disclosed uses of the antibodies, immunogenic conjugates, and DNA constructs include inducing passive or active immunity to treat or prevent pathogen infections, particularly by a Pneumocystis organism, in a subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.